233 related articles for article (PubMed ID: 22418738)
1. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy.
Dutoit V; Herold-Mende C; Hilf N; Schoor O; Beckhove P; Bucher J; Dorsch K; Flohr S; Fritsche J; Lewandrowski P; Lohr J; Rammensee HG; Stevanovic S; Trautwein C; Vass V; Walter S; Walker PR; Weinschenk T; Singh-Jasuja H; Dietrich PY
Brain; 2012 Apr; 135(Pt 4):1042-54. PubMed ID: 22418738
[TBL] [Abstract][Full Text] [Related]
2. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
Avril T; Saikali S; Vauleon E; Jary A; Hamlat A; De Tayrac M; Mosser J; Quillien V
J Neuroimmunol; 2010 Aug; 225(1-2):22-33. PubMed ID: 20493562
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.
Stronen E; Abrahamsen IW; Gaudernack G; Wälchli S; Munthe E; Buus S; Johansen FE; Lund-Johansen F; Olweus J
Scand J Immunol; 2009 Apr; 69(4):319-28. PubMed ID: 19284496
[TBL] [Abstract][Full Text] [Related]
5. Identification of T cell epitopes by the use of rapidly generated mRNA fragments.
Britten CM; Meyer RG; Graf C; Huber C; Wölfel T
J Immunol Methods; 2005 Apr; 299(1-2):165-75. PubMed ID: 15914199
[TBL] [Abstract][Full Text] [Related]
6. Efficiency and mechanism of antigen-specific CD8+ T-cell activation using synthetic long peptides.
Zandvliet ML; Kester MG; van Liempt E; de Ru AH; van Veelen PA; Griffioen M; Guchelaar HJ; Falkenburg JH; Meij P
J Immunother; 2012; 35(2):142-53. PubMed ID: 22306902
[TBL] [Abstract][Full Text] [Related]
7. Generation of peptide-specific CD8+ T cells by phytohemagglutinin-stimulated antigen-mRNA-transduced CD4+ T cells.
Naota H; Miyahara Y; Okumura S; Kuzushima K; Akatsuka Y; Hiasa A; Kitano S; Takahashi T; Yuta A; Majima Y; Shiku H
J Immunol Methods; 2006 Jul; 314(1-2):54-66. PubMed ID: 16828790
[TBL] [Abstract][Full Text] [Related]
8. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
[TBL] [Abstract][Full Text] [Related]
9. The role of surface HLA-A,B,C molecules in tumour immunity.
Möller P; Hämmerling GJ
Cancer Surv; 1992; 13():101-27. PubMed ID: 1423320
[TBL] [Abstract][Full Text] [Related]
10. The role of apoptosis in normal ontogenesis and solid human neoplasms.
Kaiser HE; Bodey B
In Vivo; 2000; 14(6):789-803. PubMed ID: 11204498
[TBL] [Abstract][Full Text] [Related]
11. Identification of two naturally presented MAGE antigenic peptides from a patient with hepatocellular carcinoma by mass spectrometry.
Zhou M; Peng JR; Zhang HG; Wang HX; Zhong ZH; Pan XY; Chen WF; Leng XS
Immunol Lett; 2005 Jun; 99(1):113-21. PubMed ID: 15885805
[TBL] [Abstract][Full Text] [Related]
12. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein.
Crane CA; Han SJ; Ahn B; Oehlke J; Kivett V; Fedoroff A; Butowski N; Chang SM; Clarke J; Berger MS; McDermott MW; Prados MD; Parsa AT
Clin Cancer Res; 2013 Jan; 19(1):205-14. PubMed ID: 22872572
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A).
Li G; Hundemer M; Wolfrum S; Ho AD; Goldschmidt H; Witzens-Harig M
Ann Hematol; 2006 Sep; 85(9):583-90. PubMed ID: 16718496
[TBL] [Abstract][Full Text] [Related]
14. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells.
Tomita Y; Imai K; Senju S; Irie A; Inoue M; Hayashida Y; Shiraishi K; Mori T; Daigo Y; Tsunoda T; Ito T; Nomori H; Nakamura Y; Kohrogi H; Nishimura Y
Cancer Sci; 2011 Apr; 102(4):697-705. PubMed ID: 21231984
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
16. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy.
Neidert MC; Kowalewski DJ; Silginer M; Kapolou K; Backert L; Freudenmann LK; Peper JK; Marcu A; Wang SS; Walz JS; Wolpert F; Rammensee HG; Henschler R; Lamszus K; Westphal M; Roth P; Regli L; Stevanović S; Weller M; Eisele G
Acta Neuropathol; 2018 Jun; 135(6):923-938. PubMed ID: 29557506
[TBL] [Abstract][Full Text] [Related]
17. T-cell-receptor-like antibodies - generation, function and applications.
Dahan R; Reiter Y
Expert Rev Mol Med; 2012 Feb; 14():e6. PubMed ID: 22361332
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes.
Dangles V; Halberstam I; Scardino A; Choppin J; Wertheimer M; Richon S; Quelvennec E; Moirand R; Guillet JG; Kosmatopoulos K; Bellet D; Zeliszewski D
Cancer Immunol Immunother; 2002 Feb; 50(12):673-81. PubMed ID: 11862419
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY
Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
